AnaptysBio, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from AnaptysBio, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Self-Funding Ratio: Over the last 3 years operating cash was negative while the company kept spending on investment (capex). Lower than 88% of Healthcare companies in United States.
- Steadiness Ratio: Sales grew in 3 of the last 3 years; profit grew in 2 of 3. Steadier than 85% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-188.8×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 88% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
3/3 · 2/3Sales grew in 3 of the last 3 years; profit grew in 2 of 3.
Steadier than 85% of Healthcare companies in United States.
Growth Efficiency Ratio
$51Sales grew 2,181% in 3 years; of every extra $100 of sales, $51 became extra profit.
Higher than 70% of Healthcare companies in United States.
Asset Productivity Ratio
+2181% / -40%In 3 years sales changed by +2181% while total assets changed by -40%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
9.5×Debt due within a year is covered 9.5 times by its yearly operating cash.
Higher than 84% of Healthcare companies in United States.
Cash Cushion Ratio
+14%Cash, after subtracting all debt, equals 14% of its market value (net cash).
Higher than 55% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
AnaptysBio, Inc. made a loss over the last year. AnaptysBio, Inc. owes $0.96 for every $1 it owns. AnaptysBio, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossAnaptysBio, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
112.81The share price is 112.81 times AnaptysBio, Inc.'s book value per share, higher than almost all Healthcare companies in United States.
Market cap
$1.4 BThe total market value of all of AnaptysBio, Inc.'s shares at today's price (share price × number of shares), larger than 69% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$13 MWhat AnaptysBio, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
$0.43Net worth divided by the number of shares. The share price of $48.10 is 112.8 times this, which is the P/B above.
Owes vs Owns
0.96×AnaptysBio, Inc. owes $0.96 for every $1 it owns (high), higher than 85% of Healthcare companies in United States.
Dividend yield
NoneAnaptysBio, Inc. does not currently pay a dividend.
Revenue growth
+157%Revenue rose 157% in the year to Dec 2025, and grew 184% a year on average over 3 years.
Profit growth
LossAnaptysBio, Inc. made a loss in each of the last two years.
Profit margin
-5.6%AnaptysBio, Inc. lost $6 for every $100 of revenue.
Interest cover
2.8×AnaptysBio, Inc.'s operating profit covered its interest costs 2.8 times in the year to Dec 2025.
Cash vs debt
Net cashAnaptysBio, Inc. held $198 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For AnaptysBio, Inc.: $1.4 B ÷ $13 M (31 Mar 2026) = 112.8.
How much does AnaptysBio, Inc. owe compared with what it owns?
AnaptysBio, Inc. owes $0.96 for every $1 it owns (high), higher than 85% of Healthcare companies in United States.
Does AnaptysBio, Inc. pay a dividend?
No. AnaptysBio, Inc. does not currently pay a dividend.
Is AnaptysBio, Inc.'s revenue growing?
Revenue rose 157% in the year to Dec 2025, and grew 184% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.